Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 65 of 71.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    EudraCT Number: 2013-005543-90 Sponsor Protocol Number: 20130108 Start Date*: 2014-08-26
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001673-75 Sponsor Protocol Number: ABX464-401 Start Date*: 2020-05-06
    Sponsor Name:ABIVAX
    Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu...
    Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001776-36 Sponsor Protocol Number: CAEB071B2201 Start Date*: 2009-02-13
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio multicéntrico, aleatorizado que evalúa la eficacia, seguridad, tolerabilidad y farmacocinética de AEB071 combinado con tacrolimus o micofenolato mofetil (MMF) frente a un régimen control ba...
    Medical condition: Trasplante hepático en pacientes de novo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000057-20 Sponsor Protocol Number: HC-G-H-1209 Start Date*: 2015-11-10
    Sponsor Name:B. Braun Melsungen AG
    Full Title: PROSPECTIVE, RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTI-CENTRIC, INTERNATIONAL, STUDY ON THE EFFICACY AND SAFETY OF AN EARLY TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A BALANCED GEL...
    Medical condition: Hypovolaemia in Severe Sepsis / Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10040070 Septic shock PT
    18.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020911-35 Sponsor Protocol Number: GS-US-196-0123 Start Date*: 2011-01-17
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®)...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Prematurely Ended) BE (Prematurely Ended) AT (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002931-27 Sponsor Protocol Number: I3Y-MC-JPCS Start Date*: 2020-10-03
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela...
    Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031291 Osteosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005724-38 Sponsor Protocol Number: TL-895-209 Start Date*: 2022-05-06
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects a...
    Medical condition: Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects with MF who have a Suboptimal Response to Ruxolitinib
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001286-20 Sponsor Protocol Number: CABL001I12201 Start Date*: 2021-07-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP...
    Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    21.0 100000004864 10060498 Juvenile chronic myeloid leukemia LLT
    24.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004194-27 Sponsor Protocol Number: 112957 Start Date*: 2015-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and si...
    Medical condition: Active immunization against Haemophilus influenzae type b starting from 6 weeks of age as a 3-dose primary series with a single booster dose given at 15 to 18 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005219-34 Sponsor Protocol Number: PERCOG Start Date*: 2017-05-16
    Sponsor Name:Technische Universitaet Muenchen Fakultaet fuer Medizin
    Full Title: Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy
    Medical condition: Locally advanced carcinoma of the GE-junction or esophagus (adenocarcinoma or squamous cell carcinoma), gastric antrum, body or fundus or carcinoma of the pancreas or carcinoma of the rectum requir...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001635-27 Sponsor Protocol Number: AB20001 Start Date*: 2020-05-04
    Sponsor Name:AB Science
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients ...
    Medical condition: Hospitalized Moderate and Severe COVID-19 Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001625-40 Sponsor Protocol Number: AX-CL-PANC-PI-008619 Start Date*: 2019-10-21
    Sponsor Name:GWT-TUD GmbH
    Full Title: A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
    Medical condition: Pancreatic Ductal Adenocarcinoma (PDAC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003304-73 Sponsor Protocol Number: MK-3682-011 Start Date*: 2015-01-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 ...
    Medical condition: Chronic Hepatitis C infected patient
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) DK (Completed) LT (Completed) AT (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004734-11 Sponsor Protocol Number: J1S-MC-JP04 Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma
    Medical condition: Ewing's Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002145-11 Sponsor Protocol Number: B1971015(6108A1-2005) Start Date*: 2013-05-23
    Sponsor Name:Pfizer Inc
    Full Title: A Phase 2, Randomized, Active-controlled, observer-blindED Trial, to Assess the Safety, Tolerability, and Immunogenicity of MCV4, TDAP Vaccine and bivalent RLP2086 Vaccine When Administered Concomi...
    Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003643-31 Sponsor Protocol Number: rg_13-022 Start Date*: 2014-01-22
    Sponsor Name:University of Birmingham
    Full Title: Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH).
    Medical condition: Idiopathic Intracranial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10004277 Benign intracranial hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002618-40 Sponsor Protocol Number: HIT-REZ-2005 Start Date*: 2005-12-13
    Sponsor Name:Rheinische Friedrich-Wilhelms-University of Bonn, University Hospital
    Full Title: HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymoma...
    Medical condition: P-HIT-REZ 2005 study: Refractory and relapsed primitive neuroectodermal brain tumours (medulloblastomas, supratentorial PNETs) E-HIT-REZ 2005 study (Phase II Study "Oral therapy with temozolomide...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004304-19 Sponsor Protocol Number: 117119 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v...
    Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 14:40:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA